Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 11, 2008, Pages 1747-1761

  Zhang, Quan ^a   Wang, Yan ^a   Wei, Lai ^a   Jiang, Dong ^a   Wang, Jiang Hua ^a   Rao, Hui Ying ^a   Zhu, Ling ^a   Chen, Hongsong ^a   Fei, Ran ^a   Cong, Xu ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Gene chip; Hepatitis B virus; Interferon ; Signal transducers and activators of transcription proteins; Signal transduction

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; DOUBLE STRANDED RNA; GAMMA INTERFERON INDUCIBLE PROTEIN 15; GAMMA INTERFERON INDUCIBLE PROTEIN 6 16; GENISTEIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; MESSENGER RNA; PROTEIN KINASE; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS GENOME; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 56549120653     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04985.x     Document Type: Article

References (59)

1. de Franchis R, Hadengue A, Lau G et al. EASL International consensus conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol. 2003 39 (Suppl. 1 S3 S25.
2. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004 127 (5 Suppl. 1 S303 9.
3. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002 2 : 395 403.
4. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995 13 : S47 9.
5. Lok AS, McMahan BJ. Chronic Hepatitis B, 2003. Cited 9 Dec 2003. Available from URL: http://www.aasld.org
6. Aurisicchio L, Delmastro P, Salucci V et al. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J. Virol. 2000 74 : 4816 23.
7. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 1993 119 : 312 23.
8. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother. 2003 51 : 761 85.
9. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp. Hematol. 1999 27 : 1583 92.
10. Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J. Leukoc. Biol. 2002 71 : 565 81.
11. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001 14 : 778 809.
12. Xin YF, Kessler DS, Veals SA, Levy DE, Darnell JE Jr. ISGF3, the transcriptional activator induced by interferon α, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 1990 87 : 8555 9.
13. Qureshi SA, Salditt-Georgieff M, Darnell JE Jr. Tyrosine -phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc. Natl. Acad. Sci. USA 1995 92 : 3829 33.
14. Sehgal PB. STAT-signalling through the cytoplasmic compartment: consideration of a new paradigm. Cell. Signal. 2000 12 : 525 35.
15. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interf. Cytok. Res. 1997 17 : 503 24.
16. Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 1995 270 : 4133 7.
17. Staeheli P, Pitossi F, Pavlovic J. Mx proteins: GTPases with antiviral activity. Trends Cell Biol. 1993 11 : 268 72.
18. Guidotti LG, Morris A, Mendez H et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J. Virol. 2002 76 : 2617 21.
19. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J. Virol. 2001 75 : 2694 791.
20. Nakao K, Nakata K, Yamashitai A et al. P48 (ISGF-3g) is involved in interferon-α-induced suppression of hepatitis B virus enhancer-1 activity. J. Biol. Chem. 1999 274 : 28075 8.
21. Alcantara FF, Tang H, Mclachlan A. Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res. 2002 30 : 2068 75.
22. Wang Y, Wei L, Jiang D et al. In vitro resistance to interferon of hepatitis B virus with precore mutation. World J. Gastroenterol. 2005 11 : 649 55.
23. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 1995 69 : 5437 44.
24. Hamasakia K, Nakaob K, Matsumotoa K, Ichikawaa T, Ishikawaa H, Eguchia K. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. 2003 543 : 51 4.
25. An SF, Franklin D, Fleming KA. Generation of digoxigenin-labelled double-stranded and single-stranded probes using the polymerase chain reaction. Mol. Cell. Probes 1992 6 : 193 200.
26. Naoumov NV, Lau JY, Daniels HM. Detection of HBV-DNA using a digoxigenin-labelled probe. A rapid technique without loss of sensitivity. J. Hepatol. 1991 12 : 382 5.
27. Yang YH, Dudoit S, Luu P et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002 30 : e15.
28. Workman C, Jensen LJ, Jarmer H et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol. 2002 3 : 1 16.
29. Lu SD. Current Protocols for Molecular Biology, 2nd edn. Beijing : Peking Union Medical College Press, 1999 398 9.
30. Miscia S, Baldassarre AD, Rana RA, Cataldi A. Phospholipase C γ1 overexpression and activation induced by interferon beta in human T lymphocytes: an ISGF3- independent response. Cytokine 1997 9 : 660 5.
31. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc. Natl. Acad. Sci. USA 2004 101 : 1743 7.
32. Watanabe S, Arai K. Roles of the JAK-STAT system in signal transduction via cytokine receptors. Curr. Opin. Gene. Dev 1996 6 : 587 96.
33. Schindler C. Cytokines and JAK-STAT signaling. Exp. Cell Res. 1999 253 : 7 14.
34. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors: studies from gene knockout mice. Cytokine Growth F. R. 2001 12 : 133 42.
35. Levy DE, Kessler DS, Pine R, Darnell JE Jr. Cytoplasmic activation of ISGF3, the positive regulator of interferon-α-stimulated transcription, reconstituted in vitro. Genes Dev. 1989 3 : 1362 71.
36. Kessler DS, Levy DE, Darnell JE Jr. Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc. Natl. Acad. Sci. USA 1988 85 : 8521 5.
37. Bluyssen HAR, Levy DE. Stat2 is a transcriptional activator that requires sequence specific contacts provided by Stat1 and p48 for stable interaction with DNA. J. Biol. Chem. 1997 272 : 4600 5.
38. Leung S, Qureshi SA, Kerr IM, Darnell JE Stark GR. Role of STAT2 in the alpha interferon signaling pathway. Mol. Cell. Biol. 1995 3 : 1312 17.
39. Nakaya T, Sato M, Hata N et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem. Biophys. Res. Commun. 2001 283 : 1150 6.
40. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001 288 : 379 90.
41. Saito S, Ogino T, Miyajima N, Kato A, Kohase M. Dephosphorylation failure of tyrosine-phosphorylated STAT1 in IFN-stimulated sendai virus C protein-expressing cells. Virology 2002 293 : 205 9.
42. Takeuchi K, Kadota S, Takeda M, Miyajima N, Nagata K. Measles virus V protein blocks interferon (IFN) -K/L but not IFN-Q signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett. 2003 545 : 177 82.
43. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995 270 : 467 70.
44. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Lightdirected, spatially addressable parallel chemical synthesis. Science 1991 251 : 767 73.
45. Ng RK, Lau CY, Lee SM, Tsui SK, Fung KP, Waye MM. cDNA microarray analysis of early gene expression profiles associated with hepatitis B virus X protein-mediated hepatocarcinogenesis. Biochem. Biophys. Res. Commun. 2004 322 : 827 35.
46. Otsuka M, Aizaki H, Kato N et al. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem. Biophys. Res. Commun. 2003 300 : 443 7.
47. Wang X, Yuan ZH, Zheng LJ et al. Gene expression profiles in an hepatitis B virus transfected hepatoblastoma cell line and differentially regulated gene expression by interferon-a. World J. Gastroenterol. 2004 10 : 1740 5.
48. Xiong W, Wang X, Liu XY et al. Analysis of gene expression in hepatitis B virus transfected cell line induced by interferon. Acta. Biochim. Biophys. Sin. 2003 35 : 1053 60.
49. Xiong W, Wang X, Liu XY et al. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication. Virology 2004 319 : 306 14.
50. David M, Romeroll G, Zhang ZY et al. In Vitro activation of the transcription factor ISGF3 by Interferon-α involves a membrane-associated tyrosine phosphatase and tyrosine kinase. J. Biol. Chem. 1993 268 : 6593 9.
51. Kato M, Yuki N, Kaneko A, Yamamotoa K, Masuzawa M, Hayashi N. Changes in virus loads and precore mutations in chronic hepatitis B patients treated with 4 weeks of daily interferon alfa-2a therapy. Hepatol. Res. 2004 28 : 73 8.
52. Hugle T, Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 2003 13 : 361 71.
53. Wang JY, Liu P. Abnormal immunity and gene mutation in patients with severe hepatitis-B. World J. Gastroenterol. 2003 9 : 2009 11.
54. Kraus TA, Lau JF, Parisien J, Horvath CM. A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J. Biol. Chem. 2003 278 : 13033 8.
55. Parker N, Porter ACG. Identification of a novel gene family that includes the interferon-inducible human genes 6-16 and ISG12. BMC Genomics 2004 5 : 8.
56. Martensen PM, Sogaard TM, Gjermandsen IM et al. The interferon alpha induced protein ISG12 is localized to the nuclear membrane. Eur. J. Biochem. 2001 268 : 5947 54.
57. D'Cunha J, Knight E Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. USA 1996 93 : 211 15.
58. Kim K, Zhang DE. ISG15, not just another ubiquitin-like protein. Biochem. Biophys. Res. Commun. 2003 307 : 431 4.
59. Bieche I, Asselah T, Laurendeau I et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005 332 : 130 44.